NFKB1 and Hepatic fibrosis: Our previous studies found that tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) protected liver injury by decreasing NF-κB/NLRP3 inflammasome signaling pathways, thereby attenuating liver fibrosis [30].